drugset / Trial / NCT04648969

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

NCT04648969

Phase 2 Completed 18 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.

Timeline

Start
2019-05-03
Primary completion
2025-08-31
Completion
2025-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject kisspeptin 112-121 Peptide Intravenous
Background Gonadorelin Protein / enzyme biologic Intravenous